Yeah I saw the Evaluatepharma article and it was surprisingly incorrect factually. They probably would not have been so dismissive had it been a US analyst covering the stock.
They were not comparing apples to apples. They talked about a deal value estimated by Bell Potter for a worldwide license vs. the actual value NEU obtained for just US license, saying Bell Potter set expectations too high..
Once NEU ultimately licenses out Ex-US rights, the Acadia deal value plus the Ex-US deal value may still be close to or higher than what Bell Potter was estimating in 2018.
Yeah I saw the Evaluatepharma article and it was surprisingly...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.94 |
Change
-0.200(1.52%) |
Mkt cap ! $1.653B | |||
| Open | High | Low | Value | Volume |
| $13.03 | $13.06 | $12.75 | $7.500M | 581.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2300 | $12.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.96 | 2086 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |